FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (\"FSD Pharma\" or the \"Company\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023.Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system. At the ECTRIMS-ACTRIMS meeting, FSD Pharma will present Phase 1 data on a randomized, double-blind, placebo controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of Lucid-21-302 in healthy volunteers.Andrzej Chruscinski, M.D., Ph.D., Vice-President, Clinical and Scientific Affairs, Lucid Psycheceuticals, commented, \"We are excited about presenting our Phase 1 first-in-human clinical data on Lucid-MS at this peer conference in Milan. Current disease modifying therapies for MS target immune mechanisms, reducing inflammation, but have only modest effects on delaying neurodegeneration. Our candidate molecule prevents demyelination in several animal models of MS and was well tolerated in rats and dogs. We look forward to sharing our clinical data as we advance our MS program.\" Lakshmi P. Kotra, B.Pharm.(Hons),Ph.D. CEO of Lucid Psycheceuticals added, \"This is potentially a first-in-class therapy that could change the treatment paradigm for all stages of MS including for progressive MS, addressing neurodegenerative mechanisms. We are eager to advance this candidate into the next stages of clinical development to be able to help patients and improve their quality of life.\"Current global research efforts in MS are focused on developing treatments to repair damaged myelin, the fatty layer surrounding nerves, and protect them from further damage. While a cure for MS...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B